Trade

with

Auxilium Pharmaceuticals Inc
(NASDAQ: AUXL)
AdChoices
31.24
+0.05
+0.16%
After Hours :
-
-
-

Open

31.17

Previous Close

31.19

Volume (Avg)

576.38k (2.12M)

Day's Range

31.11-31.32

52Wk Range

16.71-33.00

Market Cap.

1.57B

Dividend Rate ( Yield )

-

Beta

0.69

Shares Outstanding

50.35M

P/E Ratio (EPS)

-

AdChoices
Financials
  • Income Statement
  • Balance Sheet
  • Cash Flow
Operating Income
-68.08M
Operating Margin
-16.99
Total Equity
-
Retained Earnings
-
Free Cashflow
-
Price/Cashflow
-
Ownership

Institutional Ownership

-

Top 10 Institutions

68.78%

Mutual Fund Ownership

51.85%

Float

99.46%

5% / Insider Ownership

2.42%

Corporate insiders or major stockholders reporting trading activity in the stock.

Top Mutual Fund Owners

Top Institutional Owners

Mutual Fund Name

Institution Name

  • Mutual Fund Name

  • Shares Held

  • % Change

  • % Outstanding

  • PowerShares Dynamic Pharmaceuticals Port

  •  

    2,204,252

  • 1.23

  • 4.51

  • Fidelity® Growth Company Fund

  •  

    1,651,300

  • 0.00

  • 3.28

  • SPDR® S&P Pharmaceuticals ETF

  •  

    1,423,377

  • 0.00

  • 2.91

  • ClearBridge Small Cap Growth Fund

  •  

    1,391,855

  • -1.05

  • 2.76

  • Fidelity® Select Biotechnology Portfolio

  •  

    1,004,721

  • 0.00

  • 2.00

  • Fidelity® Select Health Care Portfolio

  •  

    1,000,000

  • 0.00

  • 1.99

  • Vanguard Small Cap Index

  •  

    874,642

  • -0.16

  • 1.74

  • Vanguard Total Stock Mkt Idx

  •  

    810,807

  • 0.43

  • 1.61

  • iShares Russell 2000 (AU)

  •  

    760,039

  • -1.81

  • 1.55

  • Invesco Global Health Care Fd

  •  

    759,948

  • 0.00

  • 1.60

  • Institution Name

  • Shares Held

  • % Change

  • % Outstanding

  • Deerfield Management Co

  •  

    6,267,382

  • +144.18%

  • 12.47

  • Fidelity Management and Research Company

  •  

    5,987,695

  • +0.01%

  • 11.91

  • Palo Alto Investors, LLC

  •  

    4,854,631

  • -49.87%

  • 9.66

  • Paulson & Company Inc

  •  

    4,000,000

  • 0.00%

  • 7.96

  • Vanguard Group, Inc.

  •  

    3,022,301

  • +0.16%

  • 6.01

  • State Street Corp

  •  

    2,284,242

  • +20.73%

  • 4.54

  • Wellington Management Company, LLP

  •  

    2,190,023

  • +33.80%

  • 4.36

  • BlackRock Fund Advisors

  •  

    2,060,593

  • -3.56%

  • 4.10

  • Artal Group S A

  •  

    2,015,000

  • +46.55%

  • 4.01

  • TAMRO Capital Partners LLC

  •  

    1,889,738

  • -4.73%

  • 3.76

Company Profile

Sector

Healthcare

Industry

Drug Manufacturers – Specific & Generic

Type

Distressed

Style

Small Growth

Auxilium Pharmaceuticals, Inc., incorporated in the state of Delaware in July 1999. The Company is a specialty biopharmaceutical company which develops and markets products for specialist audiences. The Company now have a portfolio o...moref 12 approved products, including one product with two indications. Among other products in the U.S., Auxilium markets Testim (testosterone gel) for the topical treatment of hypogonadism, TESTOPEL (testosterone pellets) a long-acting implantable testosterone replacement therapy ("TRT") product, STENDRA (avanafil), an oral erectile dysfunction ("ED") therapy, Edex (alprostadil for injection), an injectable treatment for ED, Osbon ErecAid, the leading vacuum device for aiding ED, XIAFLEX (collagenase clostridium histolyticum or "CCH") for the treatment of Peyronie's diseas...moree ("PD" or "Peyronie's") and XIAFLEX for the treatment of Dupuytren's contracture ("DC" or "Dupuytren's"). We also have programs in Phase 2 clinical development for the treatment of Frozen Shoulder syndrome and cellulite, Striant, a buccal TRT, XIAFLEX for the treatment of PD in men with a palpable plaque and a curvature deformity of thirty degrees or greater at the start of therapy which was launched in the U.S. in January 2014 and is the first and only FDA-approved non-surgical treatment for PD. Approximately 75% of the Company’s product shipments are to only three wholesalers: Cardinal Health, Inc., McKesson Corporation and AmerisourceBergen Corporation. The Company faces competition from competitors in North America, Europe and elsewhere from pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies that are developing and commercializing pharmaceutical products.lessless

Key People

Mr. Adrian Adams

CEO/Director/President

Mr. Rolf A. Classon

Chairman of the Board/Director

Mr. Andrew Saik

Director/CFO

Mr. Mark A. Glickman

Executive VP, Divisional

Benjamin J Del Tito,Jr

Executive VP, Divisional

Incorporated

1999

Employees

-

Send Feedback

We appreciate your input!

  • I'm having trouble signing into my Microsoft account

  • I’m having problems with the services stripe (Mail, Facebook, etc.)

  • There is an issue with my weather information

  • I see an error in the content

  • Other

Please give an overall site rating: